Kite Pharma Inc. (KITE) 82.35 $KITE
Value Investing Strategy For Biotech
Henry Wolfe - at Seeking Alpha - Mon Jan 12, 11:57AM CST
CARA: 10.99 (+0.04), BLCM: 31.33 (-0.42), GILD: 101.21 (-1.00), KITE: 82.35 (+3.21), CLDX: 19.03 (-0.08), CALA: 22.86 (-0.78), AGIO: 131.55 (+3.43)
Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest
Brian Orelli, The Motley Fool - Motley Fool - Sat Jan 10, 6:49AM CST
JPMorgan 's annual healthcare conference is set to kick off next week, but many companies already announced clinical trial data and deals ahead of the conference. Part of the early release has to do with SEC regulations. In addition to public...
BIIB: 347.84 (+5.50), VRTX: 118.31 (-3.90), PFE: 32.77 (+0.12), INCY: 73.30 (+1.27), AMGN: 156.22 (+0.49), BMY: 62.18 (+1.86), ALKS: 68.61 (+3.47), CELG: 117.00 (+3.33), AGEN: 6.17 (+0.88), JNJ: 104.58 (-0.36), NBIX: 29.51 (+1.22), JPM: 58.83 (-0.51), ISIS: 73.34 (+1.08), ALNY: 103.78 (+2.48), KITE: 82.35 (+3.21), GILD: 101.21 (-1.00), GWPH: 78.73 (+0.20), INFI: 15.15 (+0.38), ABBV: 65.76 (-0.02), CEMP: 26.62 (+0.84), SNY: 44.92 (+0.37), ARNA: 5.65 (+0.22), REGN: 413.33 (+2.29), NVS: 95.48 (-0.64)
Seeking Alpha's Biotech Weekly: Gilead Rises With Phenex, Bass's Patent Attack, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 09, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
AGEN: 6.17 (+0.88), JNJ: 104.58 (-0.36), NBIX: 29.51 (+1.22), ISIS: 73.34 (+1.08), KITE: 82.35 (+3.21), GILD: 101.21 (-1.00), INCY: 73.30 (+1.27), CVS: 97.20 (-0.72), AMGN: 156.22 (+0.49), ABBV: 65.76 (-0.02), ARNA: 5.65 (+0.22), NVS: 95.48 (-0.64)
Money flow into Kite Pharma still bullish
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 10:55AM CST
KITE: 82.35 (+3.21)
Today's Review on Biotech Equities - Kite Pharma, Organovo Holdings, BioMarin Pharma, NephroGenex, and Neuralstem
PR Newswire - Fri Jan 09, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: Kite Pharma Inc. (NASDAQ: KITE), Organovo Holdings Inc. (NYSE MKT: ONVO), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), NephroGenex Inc. (NASDAQ: NRX), and Neuralstem Inc. (NYSE MKT: CUR). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets surged on Thursday, January 08, 2015, as the Dow Jones Industrial Average finished at 17,907.87, up 1.84% and the NASDAQ Composite closed at 4,736.19, up 1.84%. The S&P 500 finished the session 1.79% higher at 2,062.14. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 819.86, up 1.72%, with the index gaining 11.71% in the previous three months. Register for your complimentary reports on these five stocks at:
BMRN: 96.58 (+2.80), KITE: 82.35 (+3.21), ONVO: 6.69 (-0.33), NRX: 7.90 (-1.19), CUR: 3.22 (-0.18)
Kite Pharma Expands Senior Management Team With Appointment of Claudine Prowse, Ph.D., as SVP, Corporate Communications and Investor Relations
GlobeNewswire - Fri Jan 09, 7:07AM CST
Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced the appointment of Claudine Prowse, Ph.D., to the newly created position of Senior Vice President, Corporate Communications and Investor Relations (IR). Dr. Prowse will be primarily responsible for driving the Company's communication strategy and initiatives. She will report to Ms. Cynthia M. Butitta, Chief Financial Officer and Chief Operating Officer.
BIIB: 347.84 (+5.50), KITE: 82.35 (+3.21)
Kite Pharma Announces Addition of Scott N. Bernstein as Vice President of Intellectual Property Law
GlobeNewswire - Thu Jan 08, 4:14PM CST
Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced the appointment of Scott N. Bernstein as Vice President, Intellectual Property Law. Mr. Bernstein brings substantial background and expertise in biotechnology and pharmaceutical patent law to Kite. He will be responsible for further developing and leveraging Kite's intellectual property in cancer immunotherapy. He will report to David Chang, M.D., Ph.D., Executive Vice President, R&D, and Chief Medical Officer.
KITE: 82.35 (+3.21)
Kite Pharma inks deal with NIH in HPV-related cancer
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 12:28PM CST
KITE: 82.35 (+3.21)
Kite Pharma Announces Exclusive License With the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat HPV-Associated Cancers
GlobeNewswire - Wed Jan 07, 12:00PM CST
Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that the Company has entered into an exclusive, worldwide license with the National Institutes of Health (NIH) for intellectual property related to T Cell Receptor (TCR)-based product candidates directed against human papillomavirus (HPV)-16 E6 and E7 oncoproteins for the treatment of cancers associated with HPV infection. The National Cancer Institute (NCI) has recently initiated a Phase 1/2 clinical trial of one of these TCR product candidates, targeting the HPV-16 E6 oncoprotein, under a Cooperative Research and Development Agreement (CRADA) between Kite and the NCI. Pursuant to the terms of the license agreement, Kite will make to NIH certain clinical, regulatory, and sales milestone payments and royalties on net sales of products covered by the license.
KITE: 82.35 (+3.21)
Biotech Stock Roundup: Kite Flies High on Amgen Deal, Isis Soars on J&J Collaboration - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jan 07, 8:09AM CST
Collaborations and agreements continued to make headlines in the biotech sector with companies like Gilead (GILD), Amgen (AMGN) and Isis (ISIS) announcing deals.
BIIB: 347.84 (+5.50), ISIS: 73.34 (+1.08), KITE: 82.35 (+3.21), GILD: 101.21 (-1.00), ICPT: 146.18 (-3.82), AMGN: 156.22 (+0.49), ALKS: 68.61 (+3.47)
Kite Pharma to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Jan 07, 7:00AM CST
Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that Arie Belldegrun, MD, FACS, President and Chief Executive Officer, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 12:00 PM Pacific Time. The event will be held in San Francisco at the Westin St. Francis Hotel. In addition, members of the Kite management team will participate in the Sanford C. Bernstein "Rising Stars Breakfast" on Tuesday, January 13, 2015 in San Francisco.
JPM: 58.83 (-0.51), KITE: 82.35 (+3.21)
Kite Pharma Up on Amgen Cancer Immunotherapy Tie-Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 6:00PM CST
Amgen Inc. (AMGN) and Kite Pharma (KITE) are tying up for the development and commercialization of chimeric antigen receptor cell immunotherapies.
KITE: 82.35 (+3.21), AMGN: 156.22 (+0.49), JUNO: 61.51 (+7.24), AMAG: 42.32 (-0.12)
Kite Pharma Gets Stock Price Increase Post Amgen Deal
at Investor's Business Daily - Tue Jan 06, 2:07PM CST
Credit Suisse raised its price target on Kite Pharma (KITE), a day after the cancer treatment developer announced a significant deal with Amgen. Jason Kantor maintained an outperform rating on Kite and raised his price target to 79 from 71. Kite...
RDUS: 38.90 (-2.02), KITE: 82.35 (+3.21), AMGN: 156.22 (+0.49), ASPX: 59.91 (+0.57), JUNO: 61.51 (+7.24)
Company News for January 06, 2015 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 9:10AM CST
Companies in the News are: KITE,AMGN,STI,ISIS,NPSP,GS
JNJ: 104.58 (-0.36), GS: 185.07 (-2.28), ISIS: 73.34 (+1.08), KITE: 82.35 (+3.21), NPSP: 45.35 (+3.44), STI: 38.41 (-0.41), AMGN: 156.22 (+0.49)
Kite Pharma (KITE) Looks Good: Stock Adds 15.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 7:51AM CST
Kite Pharma, Inc. (KITE) was a big mover last session with its shares rising over 15% on the day.
KITE: 82.35 (+3.21), AMAG: 42.32 (-0.12)
Scaling New Heights: Complimentary Research on Stereotaxis, Kite Pharma, ISIS Pharma, Merck and General Motors
PR Newswire - Tue Jan 06, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Stereotaxis (NASDAQ: STXS), Kite Pharma (NASDAQ: KITE), ISIS Pharma (NASDAQ: ISIS), Merck (NYSE: MRK), and General Motors (NYSE: GM). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ISIS: 73.34 (+1.08), KITE: 82.35 (+3.21), MRK: 62.30 (-0.26), GM: 35.84 (+0.25), STXS: 1.63 (-0.11)
After CAR-T: Getting Ahead of the Next Hot Trend in Cancer Stocks
at The Street - Tue Jan 06, 7:30AM CST
Here's how investors can help fund the next cure for cancer: anti-CD47 antibody therapies.
BLUE: 101.95 (-1.68), KITE: 82.35 (+3.21), JUNO: 61.51 (+7.24), TRIL: 14.40 (+1.61), CELG: 117.00 (+3.33)
Kite Pharma Granted Orphan Drug Designation in the European Union for KTE-C19, Kite's Lead Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy
GlobeNewswire - Tue Jan 06, 7:07AM CST
Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that the European Commission (EC), acting on the positive recommendation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has designated KTE-C19 as an orphan medicinal product for the treatment of diffuse large B cell lymphoma (DLBCL). Kite previously announced in March 2014 that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation for KTE-C19 for the treatment of DLBCL. Further, Kite has filed an investigational new drug (IND) application to conduct a Phase 1/2 clinical trial for KTE-C19 with the FDA.
KITE: 82.35 (+3.21)
Ackman Short Keeps Looking Better As Herbalife Takes A Dive
at The Street - Mon Jan 05, 2:46PM CST
Voltari Corp (NASDAQ:VLTC), Kite Pharma Inc (NASDAQ:KITE) and Uniqure NV (NASDAQ:QURE) are approaching market close in the green this Monday. In the red are Laredo Petroleum Inc (NYSE:LPI), Herbali...
HLF: 32.73 (-0.59), QURE: 20.42 (+2.08), KITE: 82.35 (+3.21), VLTC: 0.82 (-0.03), LPI: 8.68 (-0.72)
Kite Pharma Up On Amgen Cancer Partnership
at Investor's Business Daily - Mon Jan 05, 11:21AM CST
Hot biotech IPO Kite Pharma (KITE) jumped to a new high Monday, up 9%, after it inked a deal with Amgen worth up to $585 million. The two companies will develop the next generation of Kite's chimeric antigen receptor (CAR) T cell therapies for...
KITE: 82.35 (+3.21), AMGN: 156.22 (+0.49), JUNO: 61.51 (+7.24), NVS: 95.48 (-0.64)
Value Investing Strategy For Biotech
Henry Wolfe - at Seeking Alpha - Mon Jan 12, 11:57AM CST
CARA: 10.99 (+0.04), BLCM: 31.33 (-0.42), GILD: 101.21 (-1.00), KITE: 82.35 (+3.21), CLDX: 19.03 (-0.08), CALA: 22.86 (-0.78), AGIO: 131.55 (+3.43)
Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest
Brian Orelli, The Motley Fool - Motley Fool - Sat Jan 10, 6:49AM CST
JPMorgan 's annual healthcare conference is set to kick off next week, but many companies already announced clinical trial data and deals ahead of the conference. Part of the early release has to do with SEC regulations. In addition to public...
BIIB: 347.84 (+5.50), VRTX: 118.31 (-3.90), PFE: 32.77 (+0.12), INCY: 73.30 (+1.27), AMGN: 156.22 (+0.49), BMY: 62.18 (+1.86), ALKS: 68.61 (+3.47), CELG: 117.00 (+3.33), AGEN: 6.17 (+0.88), JNJ: 104.58 (-0.36), NBIX: 29.51 (+1.22), JPM: 58.83 (-0.51), ISIS: 73.34 (+1.08), ALNY: 103.78 (+2.48), KITE: 82.35 (+3.21), GILD: 101.21 (-1.00), GWPH: 78.73 (+0.20), INFI: 15.15 (+0.38), ABBV: 65.76 (-0.02), CEMP: 26.62 (+0.84), SNY: 44.92 (+0.37), ARNA: 5.65 (+0.22), REGN: 413.33 (+2.29), NVS: 95.48 (-0.64)
Seeking Alpha's Biotech Weekly: Gilead Rises With Phenex, Bass's Patent Attack, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 09, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
AGEN: 6.17 (+0.88), JNJ: 104.58 (-0.36), NBIX: 29.51 (+1.22), ISIS: 73.34 (+1.08), KITE: 82.35 (+3.21), GILD: 101.21 (-1.00), INCY: 73.30 (+1.27), CVS: 97.20 (-0.72), AMGN: 156.22 (+0.49), ABBV: 65.76 (-0.02), ARNA: 5.65 (+0.22), NVS: 95.48 (-0.64)
Money flow into Kite Pharma still bullish
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 10:55AM CST
KITE: 82.35 (+3.21)
Today's Review on Biotech Equities - Kite Pharma, Organovo Holdings, BioMarin Pharma, NephroGenex, and Neuralstem
PR Newswire - Fri Jan 09, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: Kite Pharma Inc. (NASDAQ: KITE), Organovo Holdings Inc. (NYSE MKT: ONVO), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), NephroGenex Inc. (NASDAQ: NRX), and Neuralstem Inc. (NYSE MKT: CUR). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets surged on Thursday, January 08, 2015, as the Dow Jones Industrial Average finished at 17,907.87, up 1.84% and the NASDAQ Composite closed at 4,736.19, up 1.84%. The S&P 500 finished the session 1.79% higher at 2,062.14. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 819.86, up 1.72%, with the index gaining 11.71% in the previous three months. Register for your complimentary reports on these five stocks at:
BMRN: 96.58 (+2.80), KITE: 82.35 (+3.21), ONVO: 6.69 (-0.33), NRX: 7.90 (-1.19), CUR: 3.22 (-0.18)
Kite Pharma Expands Senior Management Team With Appointment of Claudine Prowse, Ph.D., as SVP, Corporate Communications and Investor Relations
GlobeNewswire - Fri Jan 09, 7:07AM CST
Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced the appointment of Claudine Prowse, Ph.D., to the newly created position of Senior Vice President, Corporate Communications and Investor Relations (IR). Dr. Prowse will be primarily responsible for driving the Company's communication strategy and initiatives. She will report to Ms. Cynthia M. Butitta, Chief Financial Officer and Chief Operating Officer.
BIIB: 347.84 (+5.50), KITE: 82.35 (+3.21)
Kite Pharma Announces Addition of Scott N. Bernstein as Vice President of Intellectual Property Law
GlobeNewswire - Thu Jan 08, 4:14PM CST
Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced the appointment of Scott N. Bernstein as Vice President, Intellectual Property Law. Mr. Bernstein brings substantial background and expertise in biotechnology and pharmaceutical patent law to Kite. He will be responsible for further developing and leveraging Kite's intellectual property in cancer immunotherapy. He will report to David Chang, M.D., Ph.D., Executive Vice President, R&D, and Chief Medical Officer.
KITE: 82.35 (+3.21)
Kite Pharma inks deal with NIH in HPV-related cancer
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 12:28PM CST
KITE: 82.35 (+3.21)
Kite Pharma Announces Exclusive License With the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat HPV-Associated Cancers
GlobeNewswire - Wed Jan 07, 12:00PM CST
Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that the Company has entered into an exclusive, worldwide license with the National Institutes of Health (NIH) for intellectual property related to T Cell Receptor (TCR)-based product candidates directed against human papillomavirus (HPV)-16 E6 and E7 oncoproteins for the treatment of cancers associated with HPV infection. The National Cancer Institute (NCI) has recently initiated a Phase 1/2 clinical trial of one of these TCR product candidates, targeting the HPV-16 E6 oncoprotein, under a Cooperative Research and Development Agreement (CRADA) between Kite and the NCI. Pursuant to the terms of the license agreement, Kite will make to NIH certain clinical, regulatory, and sales milestone payments and royalties on net sales of products covered by the license.
KITE: 82.35 (+3.21)
Biotech Stock Roundup: Kite Flies High on Amgen Deal, Isis Soars on J&J Collaboration - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jan 07, 8:09AM CST
Collaborations and agreements continued to make headlines in the biotech sector with companies like Gilead (GILD), Amgen (AMGN) and Isis (ISIS) announcing deals.
BIIB: 347.84 (+5.50), ISIS: 73.34 (+1.08), KITE: 82.35 (+3.21), GILD: 101.21 (-1.00), ICPT: 146.18 (-3.82), AMGN: 156.22 (+0.49), ALKS: 68.61 (+3.47)
Kite Pharma to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Jan 07, 7:00AM CST
Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that Arie Belldegrun, MD, FACS, President and Chief Executive Officer, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 12:00 PM Pacific Time. The event will be held in San Francisco at the Westin St. Francis Hotel. In addition, members of the Kite management team will participate in the Sanford C. Bernstein "Rising Stars Breakfast" on Tuesday, January 13, 2015 in San Francisco.
JPM: 58.83 (-0.51), KITE: 82.35 (+3.21)
Kite Pharma Up on Amgen Cancer Immunotherapy Tie-Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 6:00PM CST
Amgen Inc. (AMGN) and Kite Pharma (KITE) are tying up for the development and commercialization of chimeric antigen receptor cell immunotherapies.
KITE: 82.35 (+3.21), AMGN: 156.22 (+0.49), JUNO: 61.51 (+7.24), AMAG: 42.32 (-0.12)
Kite Pharma Gets Stock Price Increase Post Amgen Deal
at Investor's Business Daily - Tue Jan 06, 2:07PM CST
Credit Suisse raised its price target on Kite Pharma (KITE), a day after the cancer treatment developer announced a significant deal with Amgen. Jason Kantor maintained an outperform rating on Kite and raised his price target to 79 from 71. Kite...
RDUS: 38.90 (-2.02), KITE: 82.35 (+3.21), AMGN: 156.22 (+0.49), ASPX: 59.91 (+0.57), JUNO: 61.51 (+7.24)
Company News for January 06, 2015 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 9:10AM CST
Companies in the News are: KITE,AMGN,STI,ISIS,NPSP,GS
JNJ: 104.58 (-0.36), GS: 185.07 (-2.28), ISIS: 73.34 (+1.08), KITE: 82.35 (+3.21), NPSP: 45.35 (+3.44), STI: 38.41 (-0.41), AMGN: 156.22 (+0.49)
Kite Pharma (KITE) Looks Good: Stock Adds 15.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 7:51AM CST
Kite Pharma, Inc. (KITE) was a big mover last session with its shares rising over 15% on the day.
KITE: 82.35 (+3.21), AMAG: 42.32 (-0.12)
Scaling New Heights: Complimentary Research on Stereotaxis, Kite Pharma, ISIS Pharma, Merck and General Motors
PR Newswire - Tue Jan 06, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Stereotaxis (NASDAQ: STXS), Kite Pharma (NASDAQ: KITE), ISIS Pharma (NASDAQ: ISIS), Merck (NYSE: MRK), and General Motors (NYSE: GM). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ISIS: 73.34 (+1.08), KITE: 82.35 (+3.21), MRK: 62.30 (-0.26), GM: 35.84 (+0.25), STXS: 1.63 (-0.11)
After CAR-T: Getting Ahead of the Next Hot Trend in Cancer Stocks
at The Street - Tue Jan 06, 7:30AM CST
Here's how investors can help fund the next cure for cancer: anti-CD47 antibody therapies.
BLUE: 101.95 (-1.68), KITE: 82.35 (+3.21), JUNO: 61.51 (+7.24), TRIL: 14.40 (+1.61), CELG: 117.00 (+3.33)
Kite Pharma Granted Orphan Drug Designation in the European Union for KTE-C19, Kite's Lead Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy
GlobeNewswire - Tue Jan 06, 7:07AM CST
Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that the European Commission (EC), acting on the positive recommendation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has designated KTE-C19 as an orphan medicinal product for the treatment of diffuse large B cell lymphoma (DLBCL). Kite previously announced in March 2014 that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation for KTE-C19 for the treatment of DLBCL. Further, Kite has filed an investigational new drug (IND) application to conduct a Phase 1/2 clinical trial for KTE-C19 with the FDA.
KITE: 82.35 (+3.21)
Ackman Short Keeps Looking Better As Herbalife Takes A Dive
at The Street - Mon Jan 05, 2:46PM CST
Voltari Corp (NASDAQ:VLTC), Kite Pharma Inc (NASDAQ:KITE) and Uniqure NV (NASDAQ:QURE) are approaching market close in the green this Monday. In the red are Laredo Petroleum Inc (NYSE:LPI), Herbali...
HLF: 32.73 (-0.59), QURE: 20.42 (+2.08), KITE: 82.35 (+3.21), VLTC: 0.82 (-0.03), LPI: 8.68 (-0.72)
Kite Pharma Up On Amgen Cancer Partnership
at Investor's Business Daily - Mon Jan 05, 11:21AM CST
Hot biotech IPO Kite Pharma (KITE) jumped to a new high Monday, up 9%, after it inked a deal with Amgen worth up to $585 million. The two companies will develop the next generation of Kite's chimeric antigen receptor (CAR) T cell therapies for...
KITE: 82.35 (+3.21), AMGN: 156.22 (+0.49), JUNO: 61.51 (+7.24), NVS: 95.48 (-0.64)
